Dishman Carbogen Amcis Limited
Dishman Carbogen Amcis Ltd is engaged in Contract Research and Manufacturing Services (CRAMS) and manufacture and supply of marketable molecules such as specialty chemicals, vitamins & chemicals and disinfectants with presence in Switzerland, UK, Europe, China and other countries.
What Dishman files
- Others56
- Investor Meet24
- Board Meeting17
- Important14
- Updates12
- PPTs10
Dishman Carbogen Amcis' Q1FY27 performance saw net revenue dip 4.3% YoY to ₹677.64 Cr, largely due to deferred CDMO projects. The company reported a net loss of ₹57.88 Cr, compared to a ₹23.41 Cr profit last year. EBITDA plunged 57.3% to ₹60.08 Cr, with margins shrinking to 8.9%. CDMO revenue...
Dishman Carbogen Amcis (DCAL) delivered solid Q4FY26 and FY26 results! Net Revenue jumped 18.9% to ₹851.4 Cr in Q4 and 8.1% to ₹2,931.9 Cr for the full year. The CDMO segment was a growth engine, up 21.3% in Q4 and 6.5% for FY26, boosted by commercial sales and late Phase...
Dishman Carbogen Amcis reported Q3FY26 revenue of ₹719.8 Cr, up 5.5% year-on-year, primarily driven by its CDMO segment. Nine-month revenue reached ₹2,080.5 Cr, a 4.3% increase, boosted by Cholesterol and Vitamin D analogues. While Q3 EBITDA dipped to ₹113.1 Cr (15.7% margin) from ₹140.1 Cr (20.5%) due to lower late...
**Business Performance:** Dishman Carbogen Amcis reported a 3.6% YoY rise in H1FY26 net revenue to ₹1,360.7 Cr, primarily driven by higher development revenue and growth in Cholesterol and Vitamin D analogues. CDMO revenue experienced a slight dip of 1.1% YoY due to lower commercial supplies, with Q2FY26 CDMO revenue impacted...
Dishman Carbogen Amcis (DCAL) delivered LTM Q1FY26 revenue of **₹2,895.8 Cr** with a strong 20.1% EBITDA margin. The CDMO segment drives 85.7% of revenue, with commercial manufacturing contributing **₹1,326.6 Cr**. The bi-continental CDMO model, leveraging Swiss R&D and India's cost efficiency, is a key growth driver, focusing on high-value niche...